Navigation Links
Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug
Date:2/3/2010

LA JOLLA, CA February 3, 2010 For Immediate Release A team of scientists at The Scripps Research Institute has identified two compounds that act on novel binding sites for an enzyme used by the human immunodeficiency virus (HIV), the virus that causes AIDS. The discovery lays the foundation for the development of a new class of anti-HIV drugs to enhance existing therapies, treat drug-resistant strains of the disease, and slow the evolution of drug resistance in the virus.

The research will appear as the cover story of the March issue of the journal Chemical Biology & Drug Design.

The anti-HIV compounds identified in the new study bind to HIV proteasean enzyme essential to the lifecycle of the virus. Drugs that block this viral enzyme are called "protease inhibitors" and currently make up an important part of the successful AIDS drug cocktail known as highly active anti-retroviral therapy (HAART).

Compared with the nine U.S. Food and Drug Administration (FDA)-approved drugs that target HIV protease, however, the two new compounds, which are small chemical units or "fragments," bind with two novel parts of the molecule. This could make future drugs incorporating the fragments' novel structural elements a useful complement to existing treatments.

"The study's results open the door to a whole new approach to drug design against HIV protease," said Scripps Research Associate Professor C. David Stout, senior author of the study. "The fragments bound at not one, but two, different crevices in protease outside the active site. This is an important proof-of-concept that the protease molecule has two non-active site binding pockets ('allosteric sites') which can now be exploited as a powerful new strategy to combat drug-resistance in HIV."

Research Associate Alex L. Perryman, first author of the paper and member of Professor Arthur Olson's laboratory at Scripps Research, added, "The experiments validate my hypothe
'/>"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Scripps scientists discover fluorescence in key marine creature
2. Scripps research team blocks bacterial communication system to prevent deadly staph infections
3. Scripps scientists develop new tests that identify lethal prion strains quickly and accurately
4. Scripps Research discovery leads to broad potential applications in CovX-Pfizer deal
5. Scripps expedition provides new baseline for coral reef conservation
6. Bright lights: Mystery of glowing antibody solved by Scripps research scientists
7. Fishing throws targeted species off balance, Scripps study shows
8. Scripps Oceanography Research pegs ID of red tide killer
9. Scripps Research Institute awarded patent for remarkable chemical technology
10. Scripps research scientists reveal key structure from ebola virus
11. Scripps study sets high economic value on threatened Mexican mangroves
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... researchers have discovered a novel molecular mechanism that can ... progression of some cancers. In the March 23 online ... scientists from the University of Montreal explain how they ... of inflammatory cytokines that normally activate the immune system, ...
... diagnosis is critical in treating Lyme disease. However, ... initially misdiagnosed because currently available serological tests have ... of infection. Misdiagnosed patients may go untreated and ... face longer and more invasive treatments, as well ...
... National Renewable Energy Laboratory (NREL) recently convened the ... with a mission to enable securitization of solar ... marketplace. SAPC,s primary efforts center on the ... documents relevant to residential and commercial deployment, and ...
Cached Biology News:University of Montreal researchers discover how drug prevents aging and cancer progression 2Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device 2Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device 3Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device 4NREL assembles industry working group to advance solar securitization 2
(Date:4/21/2015)... April 21, 2015  Scientists from the J. ... organization, published a paper today outlining new synthetic ... called diatoms. The researchers, led by first author ... Philip Weyman , Ph.D., conclude that these ... of diatom genetics and thus facilitate advances in ...
(Date:4/21/2015)... , April 21, 2015 Merrimack Pharmaceuticals, ... from a multi-arm Phase 1 study of MM-141, a ... presented in an oral session by Dr. Mansoor ... Cancer Research Annual Meeting in Philadelphia, PA. ... of MM-141 as a monotherapy and in combination with ...
(Date:4/21/2015)... -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced ... April 23, 4:30 p.m. ET. Participants are invited to ... Investor call information: U.S./ Canada ... (925) 418-7845 Participant Passcode: 32888538 Questions can ... tina.amirkiai@fleishman.com . Access will be provided ...
(Date:4/21/2015)... 21, 2015  Cryoport, Inc. (OTCBB: CYRX) ... logistics solutions for the life sciences industry, ... lines, clinical research organizations, vaccine manufacturers and ... Mark W. Sawicki , Chief Commercial Officer, ... Summit in San Francisco, CA ...
Breaking Biology Technology:Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 2Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 2First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 4First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 5Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3
... Oct. 29 Vical Incorporated,(Nasdaq: VICL ) today ... three months and nine months ended September 30, 2008,before ... conduct a,conference call and webcast to discuss the financial ... on Wednesday, November 5. The call is,open on a ...
... Clearance from ... Development Progress Triggered $1M Milestone Payment from Cook Medical - ... 4:30 p.m. Eastern Time -, REDWOOD CITY, Calif., October 28 ... its fiscal 2009 first quarter ended September 30, 2008., "We had ...
... $490 Million, Up 14 Percent over Third Quarter 2007 ... Sales and Earnings Guidance, Introduces 2009 Adjusted Net ... Oct. 28 Cephalon, Inc. (Nasdaq:,CEPH) today reported third quarter ... for the third quarter of 2007, and at the high,end ...
Cached Biology Technology:Vical Announces News Release and Conference Call Schedule For Third Quarter 2008 Financial Results 2Vical Announces News Release and Conference Call Schedule For Third Quarter 2008 Financial Results 3Cardica Announces Fiscal 2009 First Quarter Financial Results 2Cardica Announces Fiscal 2009 First Quarter Financial Results 3Cardica Announces Fiscal 2009 First Quarter Financial Results 4Cardica Announces Fiscal 2009 First Quarter Financial Results 5Cardica Announces Fiscal 2009 First Quarter Financial Results 6Cephalon Reports Another Strong Quarter 2Cephalon Reports Another Strong Quarter 3Cephalon Reports Another Strong Quarter 4Cephalon Reports Another Strong Quarter 5Cephalon Reports Another Strong Quarter 6Cephalon Reports Another Strong Quarter 7Cephalon Reports Another Strong Quarter 8Cephalon Reports Another Strong Quarter 9Cephalon Reports Another Strong Quarter 10Cephalon Reports Another Strong Quarter 11Cephalon Reports Another Strong Quarter 12Cephalon Reports Another Strong Quarter 13Cephalon Reports Another Strong Quarter 14Cephalon Reports Another Strong Quarter 15Cephalon Reports Another Strong Quarter 16Cephalon Reports Another Strong Quarter 17Cephalon Reports Another Strong Quarter 18Cephalon Reports Another Strong Quarter 19
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Serum Albumin protein through lysine by amide bonds....
... Edwards (1996) • Provides key ... immunoassays, including RIA, ELISA and ... the photoluminescent and chemiluminescent labels ... also given on assay design ...
EoProbe Eosinophil Staining Kit, 1 Kit...
Biology Products: